From the Faculty of Medicine and Health, Save Sight Institute, The University of Sydney, (L.T., H.K., D.S., C.H.C., S.L.W.) Sydney, New South Wales, Australia.
From the Faculty of Medicine and Health, Save Sight Institute, The University of Sydney, (L.T., H.K., D.S., C.H.C., S.L.W.) Sydney, New South Wales, Australia.
Am J Ophthalmol. 2024 Dec;268:263-274. doi: 10.1016/j.ajo.2024.07.039. Epub 2024 Aug 5.
The recent advances in artificial intelligence (AI) represent a promising solution to increasing clinical demand and ever limited health resources. Whilst powerful, AI models require vast amounts of representative training data to output meaningful predictions in the clinical environment. Clinical registries represent a promising source of large volume real-world data which could be used to train more accurate and widely applicable AI models. This review aims to provide an overview of the current applications of AI to ophthalmic clinical registry data.
A systematic search of EMBASE, Medline, PubMed, Scopus and Web of Science for primary research articles that applied AI to ophthalmic clinical registry data was conducted in July 2024.
Twenty-three primary research articles applying AI to ophthalmic clinic registries (n = 14) were found. Registries were primarily defined by the condition captured and the most common conditions where AI was applied were glaucoma (n = 3) and neovascular age-related macular degeneration (n = 3). Tabular clinical data was the most common form of input into AI algorithms and outputs were primarily classifiers (n = 8, 40%) and risk quantifier models (n = 7, 35%). The AI algorithms applied were almost exclusively supervised conventional machine learning models (n = 39, 85%) such as decision tree classifiers and logistic regression, with only 7 applications of deep learning or natural language processing algorithms. Significant heterogeneity was found with regards to model validation methodology and measures of performance.
Limited applications of deep learning algorithms to clinical registry data have been reported. The lack of standardized validation methodology and heterogeneity of performance outcome reporting suggests that the application of AI to clinical registries is still in its infancy constrained by the poor accessibility of registry data and reflecting the need for a standardization of methodology and greater involvement of domain experts in the future development of clinically deployable AI.
人工智能(AI)的最新进展为满足不断增长的临床需求和日益有限的医疗资源提供了一个很有前景的解决方案。虽然 AI 模型功能强大,但它们需要大量具有代表性的训练数据,才能在临床环境中输出有意义的预测结果。临床注册代表了一种很有前途的大容量真实世界数据来源,可以用于训练更准确和广泛适用的 AI 模型。本综述旨在概述 AI 在眼科临床注册数据中的应用。
2024 年 7 月,对 EMBASE、Medline、PubMed、Scopus 和 Web of Science 进行了系统检索,以查找将 AI 应用于眼科临床注册数据的原始研究文章。
共发现 23 篇将 AI 应用于眼科临床注册的原始研究文章(n = 14)。注册主要是根据所捕获的条件来定义的,应用 AI 的最常见疾病是青光眼(n = 3)和新生血管性年龄相关性黄斑变性(n = 3)。表格形式的临床数据是最常见的 AI 算法输入形式,输出主要是分类器(n = 8,40%)和风险量化模型(n = 7,35%)。应用的 AI 算法几乎完全是监督式传统机器学习模型(n = 39,85%),例如决策树分类器和逻辑回归,只有 7 个应用了深度学习或自然语言处理算法。在模型验证方法和性能衡量指标方面存在显著的异质性。
仅报告了深度学习算法在临床注册数据中的有限应用。缺乏标准化的验证方法和性能结果报告的异质性表明,AI 在临床注册中的应用仍处于起步阶段,受到注册数据可及性差的限制,这反映了未来需要标准化方法,并让更多的领域专家参与到可临床部署的 AI 的开发中。